Vistagen Therapeutics, Inc. · NASDAQ:VTGN
Vistagen Therapeutics — Shareholder Meeting (September 2018)
29 slides from Vistagen Therapeutics's shareholder meeting presentation, Sep 18, 2018
Slide 1: Annual Meeting of Stockholders
\o) VistaGens ‘Therapeutics Annual Meeting of Stockholders September 14, 2018 LOPING NEW GENERATION MEDICINES FOR DEPRESSION AND OTHER CNS DISORDERS
Slide 2: Overview
Overview wes NASDAQ: VTGN ea y ir > Focused on CNS diseases and disorders with high unmet need AV-101, in Phase 2, with potential to be the first oral new generation NMDA receptor modulator for at home treatment of Major Depressive Disorder PH94B, entering Phase 3, with potential to be the first acu
Slide 3: Pipeline
Ke, Pipeline VistaGen. Major Depressive Disorder {Inadequate Response to SSRis/SNRIs) Ms Dene Dor ET NRTA) Ea Sscteton | INAS Crete Neuropathic Pain Parkinson’s Disease ee Levodopa-Induced Dyskinesia Epilepsy* eS | or risen Sy ee (PRN treatment) “Next steps TED
Slide 4: AV-101 Major Depressive Disorder
AV-101 Major Depressive Disorder |feesreeenes
Slide 5: Depression in the U.S.
Depression in the U.S. VistaGen. 1in4women 1in6men 1in8 he | RRA pepecas He ee diagnosed with depressive disorders age 12 and over takes an antidepressant’ U.S. DRUG-TREATED DEPRESSION MARKET IS LARGE WITH HIGH UNMET NEE! 11.6M » 7.3M 5.1M US. Drug-Treated Inadequate response \freatment-resistant af
Slide 6: Current Depression Drugs Fall Short for Millions of Patients
Ke). Current Depression Drugs Fall Short for Millions of Patients wenger Current Adjunctive Antipsychotics prazac Zolo W, mbatst eur * Often do not work * Often do not work ~ First antidepressant effective in only 1 of 3 patients ~ Only 10 to 20% of patients respond * Slow to work '* Safety concerns
Slide 7: Current Depression Drug Treatment Paradigm
Current Depression Drug Treatment Paradigm SSRI/SNRI SSRI/SNRI SSRI/SNRI “$6 Weeks ormore ‘6 weeks ormoce 2.6 Weeks or more VistaGen» Gonna Zolo BSEUstio BRB vesorel pena | re
Slide 8: First Goal for AV-101
First Goal for AV-101 VistaGen« REPLACE ANTIPSYCHOTICS IN THE DEPRESSION DRUG TREATMENT PARADIGM. ‘SSRI/SNRI ‘SSRI/SNRI ‘SSRI/SNRI VYVIT TT Posh 1/111 1'/
Slide 9: The Ketamine Story: Breakthrough Shift in Depression Treatment Paradigm
Ie The Ketamine Story: VistaGen. Breakthrough Shift in Depression Treatment Paradigm FUNDAMENTALLY _FASTER-ACTING THAN SIDE EFFECTS & DIFFERENT MOA ‘ALL CURRENT DRUGS SAFETY CONCERNS a i oepeaenroves “{kJetamine, given + DEA Schedule Ill Drug my were Hsayencisly- might = Risk of Abuse b * NMDAR anta
Slide 10: Ketamine offers new hope, but is it a long-term solution?
Ketamine offers new hope, but is it a long-term solution? Bi ceca ty “Club Drug Ketamine Provides Hope in Fight Against Depression” TIME v poe to Lift Depression in Hours Rather Than Weeks” ‘THE WALL STREET JOURNAL.
Slide 11: AV-101: A New Generation Antidepressant Candidate
} AV-101 VisiaGen. | A New Generation Antidepressant Candidate | v Oral NMDA receptor GlyB antagonist Vv Ketamine-like antidepressant effects v No ketamine-like side effects Y Different from all FDA-approved - antidepressants ° Very well-tolerated in NIH-funded safety studies * Three clinical studie
Slide 12: AV-101's Mechanism of Action
Ke, VistaGen AV-101’s Mechanism of Action Trerapetics Ketamine, PC, Lanicemine
Slide 13: AV-101 vs. Ketamine in Published Preclinical Studies
i 1) © av-101 vs. Ketamine in Published Preclinical Studies VeEGER. ' Rapid-acting Antidepressant Effects AV-101 Ketamine Forced-swim = &$zz=— > A Taltsuspension —————= v Learned helplessness OE Novelty-suppressed feeding a ec “Our results highlight the potential of 4-CI-KYN asa | _Negative Side Eff
Slide 14: NIMH Phase 2 Clinical Study
i NIMH Phase 2 Clinical Study ‘eilondl redler lational Institute AV-101 for Major Depressive Disorder NIH) of Mental Hi Principal Investigator: Dr. Carlos Zarate, Jr., National Institute of Mental Health + NIH-funded * Monotherapy for treatment-resistant depression * Oral dose, once per day for 14 d
Slide 15: ELEVATE Phase 2 Clinical Study
ELEVATE Phase 2 Clinical Study AV-101 for Major Depressive Disorder Principal Investigator: Dr. Maurizio Fava, Harvard Medical School + VistaGen-funded + Adjunctive therapy for inadequate response to current antidepressants * Oral dose, once per day for 14 days + Target enrollment = ca. 180 patients
Slide 16: Additional Goals for AV-101 in Depression
Additional Goals for AV-101 in Depression 1. Prevent relapse following ketamine therapy 2. Stand alone, first line oral therapy NESUSESPS, Phase 2 studies of AV-101 following ketamine therapy and asa stand alone, at-home first-line therapy 8 Ca
Slide 17: AV-101 Additional Opportunities
AV-101 Additional Opportunities |feesreeenes
Slide 18: Baylor/VA Phase 1 Clinical Study
Ke, Baylor/VA Phase 1 Clinical Study Ges E | av-101 for Suicidal ideation | US. Department of Veterans Affairs Principal Investigator: Dr. Marijn Lijffijt, Baylor College of Medicine + First-step study to test anti-suicidal effects of AV-101 in healthy volunteer U.S. Military Veterans + Completion a
Slide 19: AV-101 for Neuropathic Pain
Ke, AV-101 for Neuropathic Pain VistaGen New Oral, Non-opioid, Non-addictive, Non-sedating Treatment Option CS Preclinical data, together with successful Phase 1 safety studies, support a Phase 2a clinical study to assess AV: 101's potential as a new generation neuropathic pain treatment alternative
Slide 20: AV-101 for Parkinson's Dyskinesia
AV-101 for Parkinson’s Dyskinesia VistaGen: |_New Option to Reduce Dyskinesia Associated with L-DOPA Therapy Levodopa-induced dyskinesia occurs in 80% of patients with PO after 5-10 years Preclinical data in monkey models, together with successful Phase 1 safety studies, support a Phase 2a, clinical
Slide 21: PH94B Social Anxiety Disorder
PH94B Social Anxiety Disorder |feesreeenes
Slide 22: Social Anxiety Disorder (SAD)
Social Anxiety Disorder (SAD) Social Phobia - more than just shyness Social anxiety disorder (SAD) is an intense, irrational, and persistent fear of being scrutinized or negatively evaluated by other people SAD has a considerable impact on patients’ lives, with lost opportunities, increased depressi
Slide 23: Current Pharmacological Treatments for SAD
‘% Current Pharmacological Treatments for SAD VistaGen. FDA-approved Off-label + Antidepressants = SSRis such as paroxetine and sertraline and SNRis such as venlafaxine % Take weeks to months to work and may worsen anxiety initially % Many patients are reluctant to take long-term, daily SSRis or SNR
Slide 24: PH94B: A Novel, Rapid-Acting, On-Demand Treatment for SAD
+ PH94B i ANovel, Rapid-Acting, On-Demand Treatment for SAD v Nasal spray ¥ As-needed (PRN) administration Y Works i v Non-sedating ¥ Non-addictive jinutes = Very well-tolerated in Phase 1 and Phase 2 clinical studies + No systemic exposure = No toxicity = Phase 3-ready
Slide 25: VistaStem Regenerative Medicine and Drug Rescue
VistaStem Regenerative Medicine and Drug Rescue |feesreeenes
Slide 26: VistaStem Therapeutics
VistaStem Therapeutics VistaGen. Stem cell technology for regenerative medicine and drug rescue + Wholly-owned subsidiary Participant in FDA's Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative focused ‘on next generation, stem cell-based predictive cardiac toxicology screening for drug de
Slide 27: Regenerative Medicine Opportunities
Regenerative Medicine Opportunities Cardiovascular disease * Cardie infarction + Coronary heart disease + LICENSED Liver disease + Acute liver failure + Chronic hepatitis ¢ + Fatty Iver disease + Deugeinduced ler faliure * AVAILABLE FOR LICENSE Cell-based Therapeutic Opportunities Hematopoiesis (Blo
Slide 28: VistaGen Summary
VistaGen Summary VistaGen: NASDAQ: VIGN Clinical stage, focused on multiple CNS markets with high unmet need in treatment of AV-101 and PH94B have potential to drive paradigm depression, pain, suicidal ideation and social anxiety disorder VistaStem, potential for novel regenerative medicine and drug
Slide 29: Thank you for your support!
\o) VistaGens ‘Therapeutics Thank you for your support! DEVELOPING NEW GENERATION MEDICINES FOR DEPRESSION AND OTHER CNS DISORDERS
VistaGen Therapeutics — Shareholder Meeting (September 2018) on 6ix